BRAF mutation and thyroid cancer recurrence

Journal of Clinical Oncology

Volumn 33, Issue 1, 2015, Pages 7-8

  Yarchoan, Mark ^a   LiVolsi, Virginia A ^a   Brose, Marcia S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN;

CANCER RECURRENCE; CLINICAL DECISION MAKING; CLINICAL PRACTICE; EDITORIAL; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HUMAN; LYMPH NODE METASTASIS; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; STRATIFICATION; SURVIVAL RATE; THYROID CANCER; THYROID CARCINOMA; FEMALE; GENETICS; MALE; MISSENSE MUTATION; PAPILLARY CARCINOMA; THYROID TUMOR;

CARCINOMA, PAPILLARY; FEMALE; HUMANS; MALE; MUTATION, MISSENSE; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS;

EID: 84920576853     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.3657     Document Type: Editorial

References (13)

1. Davies L, Welch HG: Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295:2164-2167, 2006
2. American Cancer Society: Cancer facts and figures 2013. http://www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2013
3. Schlumberger MJ: Papillary and follicular thyroid carcinoma. N Engl J Med 338:297-306, 1998
4. Davies H, Bignell GR, Cox C, et al.: Mutations of the BRAF gene in human cancer. Nature 417:949-954, 2002
5. Xing M, Westra WH, Tufano R.P., et al.: BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90:6373-6379, 2005
6. Lee J-H, Lee E-S, Kim Y-S: Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: A meta-analysis. Cancer 110:38-46, 2007
7. Xing M, Alzahrani AS, Carson K.A., et al.: Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 309:1493-1501, 2013
8. Cappola AR, Mandel SJ: Molecular testing in thyroid cancer: BRAF mutation status and mortality. JAMA 309:1529-1530, 2013
9. Xing M, Alzahrani AS, Carson K.A., et al.: Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol 33:42-50, 2015
10. Ganly I, Ibrahimpasic T, Rivera M., et al.: Prognostic implications of papillary thyroid carcinoma with tall-cell features. Thyroid 24:662-670, 2014
11. Elisei R, Viola D, Torregrossa L., et al.: The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: Single-institution results from a large cohort study. J Clin Endocrinol Metab 97:4390-4398, 2012
12. Brose MS, Cabanillas ME, Cohen EEW, et al.: An open-label, multicenter phase 2 study of the BRAF inhibitor vemurafenib in patients with metastatic or unresectable papillary thyroid cancer (PTC) positive for the BRAF V600 mutation and resistant to radioactive iodine (NCT01286753, NO25530). ESMO/ECCO Annual Meeting, Amsterdam, the Netherlands, September 27-October 1, 2013 (abstr LBA28)
13. Paik S, Tang G, Shak S., et al.: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734, 2006